Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584883 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00584883 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 24 participants.
The verdict
NCT00584883, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Interventions
- DRUG ABT 510
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584883
The ClinicalTrials.gov registry entry for NCT00584883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT 510 is the first listed.
NCT00584883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00584883 about?
NCT00584883 is a clinical study titled "A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme". To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.
What is the current status of trial NCT00584883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2003-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00584883?
The interventions under investigation include: ABT 510 (DRUG).
Who is sponsoring clinical trial NCT00584883?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.